Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

ArriVent BioPharma, Inc.

CIK 1868279Updated Nov 11, 2026

AVBP price & chart

Provider market data

Loading TradingView…

NASDAQ:AVBP on TradingView ↗

TradingView · Data may be delayed

About the company

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team’s deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of next-generation antibody drug conjugates, through approval and commercialization.

8-K · 2026-11-09 · 0001104659-26-124484

Company description from the cited filing.

In the news

Seeking Alpha

Financials

FY 2025 · USD
Revenue— · FY 2025
Net income-166,308,000USD · FY 2025
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

Operating income-177,534,000USD · FY 2025
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

Diluted EPS-4.32USD per share · FY 2025
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

Some figures are unavailable for this reporting year.

balance sheet · annual statements
Line itemQ3 2025Q3 2024Q2 2026Q2 2025Q2 2024Q1 2026Q1 2025Q1 2024FY 2025FY 2024FY 2023
ASSETS
AssetsUSD326,555,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

292,711,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

394,718,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

269,506,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

308,855,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

349,295,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

215,495,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

327,838,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

333,169,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

274,942,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

163,098,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Current assets:
Cash and Cash Equivalents, at Carrying ValueUSD112,672,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

282,855,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

154,682,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

112,765,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

298,669,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

62,103,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

49,865,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

317,393,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

45,540,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

74,293,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

150,389,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Assets, CurrentUSD321,218,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

292,398,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

394,173,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

250,149,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

308,511,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

348,700,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

185,785,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

327,480,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

332,897,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

226,979,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

159,968,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Prepaid Expense and Other Assets, CurrentUSD20,952,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

9,543,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

21,054,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

14,462,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

9,842,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

22,320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

9,708,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

10,087,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

20,076,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

8,116,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

9,579,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Operating Lease, Right-of-Use AssetUSD49,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

187,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

370,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

85,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

219,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

370,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

120,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

250,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

13,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

154,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

291,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Other Assets, NoncurrentUSD180,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

126,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

134,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

479,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

125,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

156,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

176,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

108,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

190,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

126,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

107,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

LIABILITIES AND EQUITY
LiabilitiesUSD21,558,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

15,218,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

27,877,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

19,636,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

12,196,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

25,315,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

12,953,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

10,115,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

25,945,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

17,288,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

11,801,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Stockholders’ equity:
Common Stock, Value, IssuedUSD4,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

3,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

5,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

4,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

3,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

5,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

4,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

3,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

4,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

3,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

—
Additional Paid in CapitalUSD673,884,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

495,190,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

864,957,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

584,003,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

493,792,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

772,206,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

505,275,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

492,982,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

711,847,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

496,195,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

4,652,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Retained Earnings (Accumulated Deficit)USD-369,097,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

-217,700,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

-497,854,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

-334,119,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

-197,136,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

-447,961,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

-302,720,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

-175,262,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

-404,641,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

-238,333,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

-157,845,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Accumulated Other Comprehensive Income (Loss), Net of TaxUSD206,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

—-267,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

-18,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

—-270,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

-17,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

—14,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

-211,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

—
Stockholders' Equity Attributable to ParentUSD304,997,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

277,493,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2024-09-30

366,841,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

249,870,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2025-06-30

296,659,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2024-06-30

323,980,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

202,542,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2025-03-31

317,723,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2024-03-31

307,224,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

257,654,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

-153,193,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Liabilities and EquityUSD326,555,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

292,711,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

394,718,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

269,506,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

308,855,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

349,295,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

215,495,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

327,838,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

333,169,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

274,942,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

163,098,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Current liabilities:
Liabilities, CurrentUSD21,558,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

15,162,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

27,844,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

19,636,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

12,098,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

24,995,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

12,953,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

9,977,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

25,945,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

17,274,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

11,624,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Operating Lease, Liability, CurrentUSD56,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

157,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

318,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

98,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

152,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

99,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

138,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

147,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

14,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

162,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

140,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Accounts Payable, CurrentUSD5,933,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

4,646,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

2,217,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

4,060,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

3,812,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

8,727,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

4,364,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

4,098,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

5,934,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

3,782,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

4,532,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Operating Lease, Liability, NoncurrentUSD—56,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

33,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

—98,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

—138,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

—14,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

177,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Additional Financial Items
Accrued Liabilities, CurrentUSD15,569,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

10,359,000
Source

10-Q · 2024-11-14 · 0001558370-24-015624

As of 2024-09-30

25,309,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

15,478,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

8,134,000
Source

10-Q · 2024-08-14 · 0001558370-24-012236

As of 2024-06-30

16,169,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

8,451,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

5,732,000
Source

10-Q · 2024-05-08 · 0001558370-24-007197

As of 2024-03-31

19,997,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

13,330,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

6,952,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Short-term InvestmentsUSD187,594,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

—218,437,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

122,922,000
Source

10-Q · 2025-08-11 · 0001558370-25-010975

As of 2025-06-30

—264,277,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

126,212,000
Source

10-Q · 2025-05-12 · 0001558370-25-007276

As of 2025-03-31

—267,281,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

144,570,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

—

Lines labelled “Derived” are calculated from reported figures.

cash flow · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024FY 2023
Cash flows from operating activities:
Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD——————-43,320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-64,387,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-166,308,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-80,488,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-69,333,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Adjustments to reconcile net income to net cash provided by operating activities:
Share-based Payment Arrangement, Noncash ExpenseUSD——————5,485,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

2,271,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

12,520,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

3,208,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

895,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Net Cash Provided by (Used in) Operating ActivitiesUSD——————-41,892,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-68,008,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-160,588,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-70,212,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-55,842,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Cash flows from investing activities:
Net Cash Provided by (Used in) Investing ActivitiesUSD——————3,582,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

36,821,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-71,228,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-192,465,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

—
Cash flows from financing activities:
Net Cash Provided by (Used in) Financing ActivitiesUSD——————54,873,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

6,759,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

203,063,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

186,581,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

42,859,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD——————16,563,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-24,428,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-28,753,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-76,096,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-12,983,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD——112,672,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2025-09-30

282,855,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

As of 2024-09-30

154,682,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2026-06-30

112,765,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

As of 2025-06-30

62,103,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2026-03-31

49,865,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

As of 2025-03-31

45,540,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

As of 2025-12-31

74,293,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2024-12-31

150,389,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

As of 2023-12-31

Supplemental disclosure of cash flow information:
Income Taxes Paid, NetUSD————————0
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

——
Additional Financial Items
Share-based Payment Arrangement, ExpenseUSD——3,716,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

865,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

6,665,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

3,311,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

5,485,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

2,271,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

12,520,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

3,208,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

895,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Depreciation, Amortization and Accretion, NetUSD——————-559,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

—-3,026,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

——
General and Administrative ExpenseUSD——6,149,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

4,144,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

10,352,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

5,903,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

8,494,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

5,483,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

24,183,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

15,304,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

9,706,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Net Income (Loss) Attributable to ParentUSD——-34,978,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-20,564,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-49,893,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-31,399,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-43,320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-64,387,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-166,308,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-80,488,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-69,333,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD——-34,978,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-20,564,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-49,893,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-31,399,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-43,320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-64,387,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-166,308,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-80,488,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-69,333,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Operating ExpensesUSD——38,316,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

24,232,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

52,691,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

33,623,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

46,111,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

66,772,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

177,534,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

94,308,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

74,590,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Operating Lease, ExpenseUSD————————200,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

200,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

200,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Payments to Acquire InvestmentsUSD——————64,383,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

9,817,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

272,934,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

——
Proceeds from Issuance of Common StockUSD——————54,724,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

6,516,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

202,631,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

——
Proceeds from Stock Options ExercisedUSD——————149,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

293,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

502,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

631,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

354,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Investment Income, Interest————
Source

10-Q · 2024-11-14 · 0001558370-24-015624

2024-07-01 to 2024-09-30

———————

Lines labelled “Derived” are calculated from reported figures.

income statement · annual statements
Line itemQ4 2025Q4 2024Q3 2025Q3 2024Q2 2026Q2 2025Q1 2026Q1 2025FY 2025FY 2024FY 2023
Operating Income (Loss)USD——-38,316,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-24,232,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-52,691,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-33,623,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-46,111,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-66,772,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-177,534,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-94,308,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-74,590,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Net Income (Loss) Attributable to ParentUSD——-34,978,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-20,564,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-49,893,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-31,399,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-43,320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-64,387,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-166,308,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-80,488,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-69,333,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Earnings Per Share, BasicUSD per share——-0.83
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-0.61
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-1.05
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-0.9
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-0.96
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-1.9
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-4.32
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-2.56
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-32.38
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Earnings Per Share, DilutedUSD per share——-0.83
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-0.61
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-1.05
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-0.9
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-0.96
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-1.9
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-4.32
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-2.56
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-32.38
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Weighted Average Number of Shares Outstanding, Basicshares——41,912,905
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

33,581,810
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

47,606,857
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

35,006,114
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

45,067,658
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

33,898,870
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

38,462,600
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

31,469,328
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

2,140,951
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Weighted Average Number of Shares Outstanding, Dilutedshares——41,912,905
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

33,581,810
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

47,606,857
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

35,006,114
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

45,067,658
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

33,898,870
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

38,462,600
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

31,469,328
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

2,140,951
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Additional Financial Items
General and Administrative ExpenseUSD——6,149,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

4,144,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

10,352,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

5,903,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

8,494,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

5,483,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

24,183,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

15,304,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

9,706,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Investment Income, NetUSD——3,338,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

3,668,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

2,798,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

2,224,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

2,791,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

2,385,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

11,226,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

13,820,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

5,257,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Net Income (Loss) Available to Common Stockholders, BasicUSD——-34,978,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

-20,564,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

-49,893,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

-31,399,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

-43,320,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

-64,387,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

-166,308,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

-80,488,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

-69,333,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Operating ExpensesUSD——38,316,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

24,232,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

52,691,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

33,623,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

46,111,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

66,772,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

177,534,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

94,308,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

74,590,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Operating Lease, ExpenseUSD————————200,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

200,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

200,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Research and Development ExpenseUSD——32,167,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2025-07-01 to 2025-09-30

20,088,000
Source

10-Q · 2025-11-10 · 0001104659-25-108847

2024-07-01 to 2024-09-30

42,339,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2026-04-01 to 2026-06-30

27,720,000
Source

10-Q · 2026-08-12 · 0001104659-26-094902

2025-04-01 to 2025-06-30

37,617,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2026-01-01 to 2026-03-31

61,289,000
Source

10-Q · 2026-05-11 · 0001104659-26-058650

2025-01-01 to 2025-03-31

153,351,000
Source

10-K · 2026-03-05 · 0001104659-26-024127

2025-01-01 to 2025-12-31

79,004,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2024-01-01 to 2024-12-31

64,884,000
Source

10-K · 2025-03-03 · 0001558370-25-001999

2023-01-01 to 2023-12-31

Investment Income, Interest————
Source

10-Q · 2024-11-14 · 0001558370-24-015624

2024-07-01 to 2024-09-30

———————

Lines labelled “Derived” are calculated from reported figures.

Filing attachments

tm2629343d1_ex99-1.htm · 8-K · 2026-11-09

Exhibit 99.1 ArriVent BioPharma Reports Third Quarter 2026 Financial Results Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC Presented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMO Dosed first patient in U.S. Phase 1a/1b study of ARR-002, a novel dual-target MUC16/NaPi2b tetravalent ADC, with initial focus in ovarian and endometrial cancers Strengthened clinical leadership with announcement of …

8-K · 2026-11-09 · 0001104659-26-124484

Read attachment ↗
tm2628237d1_ex99-1.htm · 8-K · 2026-10-26

Exhibit 99.1 ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program ───────────────────────────────────────────────────────────────────────────── NEWTOWN SQUARE, PA, October 25, 2026 (GLOBE NEWSWIRE…

8-K · 2026-10-26 · 0001104659-26-118550

Read attachment ↗
tm2627799d1_ex99-1.htm · 8-K · 2026-10-19

Exhibit 99.1 ArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung Cancer NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the publication of FURTHER Phase 1b (FURMO-002; NCT05364073) results of firmonertinib in Cancer Cell, highlighti…

8-K · 2026-10-19 · 0001104659-26-116736

Read attachment ↗
tm2627450d1_ex99-1.htm · 8-K · 2026-10-13

Exhibit 99.1 ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002 NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it dosed its first patient in the Phase 1 trial in the U.S. with ARR-002 (NCT07755436), a potential first-in-class MUC16/NaP…

8-K · 2026-10-13 · 0001104659-26-115161

Read attachment ↗
tm2627092d1_ex99-1.htm · 8-K · 2026-10-06

Exhibit 99.1 ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC NEWTOWN SQUARE, PA, October 6, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with…

8-K · 2026-10-06 · 0001104659-26-113898

Read attachment ↗
tm2622880d1_ex99-1.htm · 8-K · 2026-08-12

EX-99.1 2 tm2622880d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ArriVent BioPharma Reports Second Quarter 2026 Financial Results Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026 ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose optimization Dosing of first patient with ARR-002, a dual-targeting MUC16/NaPi2b tetravalent ADC with initial focus in ovarian and endometrial c…

8-K · 2026-08-12 · 0001104659-26-094869

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.